NEW YORK (360Dx) – Agendia said this week that US Oncology has joined its FLEX breast cancer registry study. The study is a large-scale, prospective, observational cancer study that links full genome profiling with clinical data to create a patient database that could be used to identify new gene associations with prognostic and/or predictive value in breast cancer. All US Oncology Research-affiliated sites can participate in FLEX with eight initial sites in Texas and Arizona open for enrollment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.